Extensive research identified the deficiency of a highly accurate DNA repair process known as homologous recombination as an ‘Achilles heel’ in cancer, and led to the development of PARP inhibitors as single-agent therapies
Research is moving forward to understand the value of this blood-based technology as a prognostic tool
Further studies are needed to understand the position of the fourth-generation agents NVL-520 and NVL-655 in the treatment paradigm of mutated lung cancer
The use of targeted agents in first and subsequent lines of therapy is improving outcomes in patients with mutated lung cancer progressing on standard chemotherapy, but a biomarker- or precision-guided approach is needed
Neoadjuvant immunotherapy combinations were associated with high long-term survival rates and were superior to adjuvant nivolumab in patients with resectable melanoma, according to a phase III study and analysis of pooled studies
High rates of pathological complete response were reported with neoadjuvant datopotamab deruxtecan plus durvalumab in patients with specific subtypes of breast cancer and at high risk of recurrence
Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation
Final analysis of the KEYNOTE-811 trial reports positive findings when adding pembrolizumab to trastuzumab and chemotherapy in treatment-naïve patients
Final late-phase trial results show that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients
New positive findings from research in advanced or metastatic breast cancer support the use of these agents in wider patient populations
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.